Carolin Arnold
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Carolin Arnold has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed Samir Elshikha
Departments of Pharmaceutics, University of Florida College of Pharmacy, Gainesville, FL 32610, USA
1 shared publication - Georges Abboud
Department of Pathology, Immunology and Laboratory Medicine, University of Florida College of Medicine, Gainesville, FL 32610, USA
1 shared publication - Jordan Stokes
Departments of Pharmaceutics, University of Florida College of Pharmacy, Gainesville, FL 32610, USA
1 shared publication - Laurence Morel
Department of Microbiology, Immunology, and Molecular Genetics, University of Texas Health San Antonio
1 shared publication - Nathalie Kanda
Department of Pathology, Immunology, and Laboratory Medicine, University of Florida , Gainesville, FL
1 shared publication - Sihong Song
Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL 32610, USA
1 shared publication
Latest Publications
- Open Access
- 1 March 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (3) , 371
Alpha 1 Antitrypsin Suppresses Autoantibody Production and Cellular Autoimmunity in Chronic Graft-Versus-Host Disease (cGVHD) in a Lupus Mouse Model
Systemic lupus erythematosus (SLE) is a severe autoimmune disease that is challenging to treat due to poor understanding of its pathogenesis and etiology. Clearly understanding and dissecting the therapeutic effects of potential treatment in animal models are important. It has been shown that human alpha-1 antitrypsin (hAAT) holds therapeutic potential for the treatment of autoimmune diseases including lupus. However, the mechanism underlying its protective effect requires further investigation. In the present study, we used a chronic graft-versus-host disease-induced lupus mouse model to test the effect of hAAT on lupus development. We performed adoptive transfer of MHC I-aβ mismatched bm12 splenocytes into hAAT transgenic mice and showed that hAAT significantly blocked the production of anti-dsDNA IgG autoantibodies. Mechanistically, hAAT inhibited T cell activation and proliferation, including that of effector memory T (Tem) and T follicular helper (Tfh) cells. In addition, hAAT suppressed germinal center formation and functions. These results advanced the current understanding of hAAT functions and provide a new insight for the treatment of SLE.
- 1 March 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (3) , 371
Open AccessAlpha 1 Antitrypsin Suppresses Autoantibody Production and Cellular Autoimmunity in Chronic Graft-Versus-Host Disease (cGVHD) in a Lupus Mouse Model
Systemic lupus erythematosus (SLE) is a severe autoimmune disease that is challenging to treat due to poor understanding of its pathogenesis and etiology. Clearly understanding and dissecting the therapeutic effects of potential treatment in animal models are important. It has been shown that human alpha-1 antitrypsin (hAAT) holds therapeutic potential for the treatment of autoimmune diseases including lupus. However, the mechanism underlying its protective effect requires further investigation. In the present study, we used a chronic graft-versus-host disease-induced lupus mouse model to test the effect of hAAT on lupus development. We performed adoptive transfer of MHC I-aβ mismatched bm12 splenocytes into hAAT transgenic mice and showed that hAAT significantly blocked the production of anti-dsDNA IgG autoantibodies. Mechanistically, hAAT inhibited T cell activation and proliferation, including that of effector memory T (Tem) and T follicular helper (Tfh) cells. In addition, hAAT suppressed germinal center formation and functions. These results advanced the current understanding of hAAT functions and provide a new insight for the treatment of SLE.